Apigenin

Cheap, low-risk flavonoid with a real mechanism story (CD38 inhibition → NAD+ preservation, GABA-A → mild calming, senomorphic). Human evidence is thin — most claims rest on in-vitro and rodent data. Bioavailability is the dominant problem: ~30% absorption with 2.5 hr half-life means standard 50 mg powder doses likely under-deliver. Liposomal/phytosome forms beat dose-stacking.

Apigenin is a flavone (4',5,7-trihydroxyflavone) found in chamomile, parsley, celery, and several other plants. It hits multiple targets at once — none with extreme potency, but the combination is what makes it interesting.

1. CD38 inhibition → NAD+ preservation (the Sinclair-lab thesis): CD38 is an NAD+-degrading enzyme that climbs with age and inflammation. Apigenin inhibits CD38 (IC50 ~10-15 µM in vitro). In obese mice, apigenin doubled hepatic NAD+ levels, decreased global protein acetylation, improved glucose/lipid homeostasis (Escande et al., 2013, with David Sinclair as co-author). The longevity/healthspan thesis is: instead of just supplementing NAD+ precursors (NMN, NR), you can also stop the enzyme that destroys NAD+ — apigenin is the most accessible CD38 inhibitor.

2. Aromatase (CYP19A1) inhibition: Apigenin inhibits aromatase, the enzyme that converts testosterone → estradiol (IC50 ~2.9 µM). Mechanistically a phytoestrogen with biphasic ER activity: at low concentrations behaves like a partial ER agonist, at high concentrations (≥10 µM) acts as antagonist and antiproliferative in ER+ breast cancer lines.

3. GABA-A receptor modulator: Binds the benzodiazepine-binding site on the GABA-A complex — same general site benzodiazepines hit, but with much lower affinity. This is the chamomile-tea calming effect. At dietary doses subtle; at high purified doses produces measurable anxiolysis and sedation in rodents.

4. Senomorphic activity (not classical senolytic): 2024-2025 research (Zhang et al., Advanced Science, 2025; bioRxiv 2024) reframes apigenin: rather than killing senescent cells (senolytic), it suppresses their inflammatory secretions — the senescence-associated secretory phenotype (SASP). Mechanism: apigenin binds PRDX6, blocking HSPA8 activation and disturbing ATM/p38MAPK signaling in senescent cells. In aged mice, this improved chemo response and ameliorated multiple age-related conditions.

5. Anti-inflammatory: Inhibits NLRP3 inflammasome activation in monocytes/macrophages independently of CD38 (Frontiers in Immunology, 2024). Suppresses IL-1β release.

6. BDNF/ERK/CREB upregulation in rodents: Apigenin upregulates the BDNF/ERK/CREB pathway in stressed/kindled mice — restores memory in animal AD and stress models. Translation to humans is unproven.